NCT07124793View on ClinicalTrials.gov

A Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2028

Conditions
EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer
Interventions
DRUG

IBI363+IBI305

Each treatment cycle lasts for 21 days (the first treatment cycle is 28 days). Subjects will receive IBI363 Q3W in combination with bevacizumab Q3W until 2 years of treatment, PD, intolerable toxicity, start of new anti-tumor treatment, withdrawal of informed consent, death, or study termination (whichever occurs first).

Trial Locations (1)

430030

Tongji Hospital affiliated to Tongji Medical College HUST, Wuhan

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT07124793 - A Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter